• News
  • Cases
  • Downloads
New Board Members of The Taplow Group
15.11.2019

New Board Members of The Taplow Group

The Taplow Group is delighted to announce the appointment of its new Board members. With a choice of so many excellent candidates,  we were...
Paving The Way For a Bright Future
14.11.2019

Paving The Way For a Bright Future

The Taplow Group recently concluded its 17th Annual Conference in Frankfurt, Germany. More than 26 delegates from 15 countries and 6 continents...
German-Indian Round Table, Hosted by Andreas Lapp, Honorary Consul of the Republic of India
08.11.2019

German-Indian Round Table, Hosted by Andreas Lapp, Honorary Consul of the Republic of India

10th October 2019, Stuttgart; Guest speech of our colleague Manuel Vermeer: “The New Silk Road and its Significance for India”, Peter...
12345678910Last

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here